Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome (aHUS)
9 September 2014
A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefits Scheme (PBS) listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome (aHUS).
There was constructive discussion that worked towards finalising the prescribing criteria for listing the product on the PBS consistent with the March 2014 recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) under a Managed Entry Scheme.
